GENMAB A/S (GE9.DE) Stock Fundamental Analysis
FRA:GE9 • DK0010272202
249.5 EUR
+8.7 (+3.61%)
Last: Feb 20, 2026, 07:00 PM
Taking everything into account, GE9 scores 7 out of 10 in our fundamental rating. GE9 was compared to 78 industry peers in the Biotechnology industry. GE9 has outstanding health and profitabily ratings, belonging to the best of the industry. This is a solid base for any company. GE9 is not priced too expensively while it is growing strongly. Keep and eye on this one! These ratings could make GE9 a good candidate for growth and quality investing.
1. Profitability
1.1 Basic Checks
- GE9 had positive earnings in the past year.
- GE9 had a positive operating cash flow in the past year.
- Each year in the past 5 years GE9 has been profitable.
- Each year in the past 5 years GE9 had a positive operating cash flow.
1.2 Ratios
- With an excellent Return On Assets value of 21.10%, GE9 belongs to the best of the industry, outperforming 94.87% of the companies in the same industry.
- Looking at the Return On Equity, with a value of 25.76%, GE9 belongs to the top of the industry, outperforming 94.87% of the companies in the same industry.
- GE9's Return On Invested Capital of 17.11% is amongst the best of the industry. GE9 outperforms 96.15% of its industry peers.
- GE9 had an Average Return On Invested Capital over the past 3 years of 15.20%. This is above the industry average of 11.39%.
- The last Return On Invested Capital (17.11%) for GE9 is above the 3 year average (15.20%), which is a sign of increasing profitability.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 21.1% | ||
| ROE | 25.76% | ||
| ROIC | 17.11% |
ROA(3y)15.92%
ROA(5y)16.24%
ROE(3y)18.48%
ROE(5y)18.5%
ROIC(3y)15.2%
ROIC(5y)16.1%
1.3 Margins
- With an excellent Profit Margin value of 41.35%, GE9 belongs to the best of the industry, outperforming 92.31% of the companies in the same industry.
- In the last couple of years the Profit Margin of GE9 has declined.
- The Operating Margin of GE9 (36.85%) is better than 93.59% of its industry peers.
- GE9's Operating Margin has declined in the last couple of years.
- Looking at the Gross Margin, with a value of 94.27%, GE9 belongs to the top of the industry, outperforming 91.03% of the companies in the same industry.
- In the last couple of years the Gross Margin of GE9 has declined.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 36.85% | ||
| PM (TTM) | 41.35% | ||
| GM | 94.27% |
OM growth 3Y-2.13%
OM growth 5Y-7.73%
PM growth 3Y1.23%
PM growth 5Y-2.03%
GM growth 3Y-1.55%
GM growth 5YN/A
2. Health
2.1 Basic Checks
- GE9 has a Return on Invested Capital (ROIC), which is well above the Cost of Capital (WACC), which means it is creating value.
- The number of shares outstanding for GE9 has been reduced compared to 1 year ago.
- The number of shares outstanding for GE9 has been reduced compared to 5 years ago.
- The debt/assets ratio for GE9 is higher compared to a year ago.
2.2 Solvency
- GE9 has an Altman-Z score of 84.93. This indicates that GE9 is financially healthy and has little risk of bankruptcy at the moment.
- GE9 has a better Altman-Z score (84.93) than 100.00% of its industry peers.
- GE9 has a debt to FCF ratio of 0.12. This is a very positive value and a sign of high solvency as it would only need 0.12 years to pay back of all of its debts.
- With an excellent Debt to FCF ratio value of 0.12, GE9 belongs to the best of the industry, outperforming 94.87% of the companies in the same industry.
- A Debt/Equity ratio of 0.02 indicates that GE9 is not too dependend on debt financing.
- With a decent Debt to Equity ratio value of 0.02, GE9 is doing good in the industry, outperforming 73.08% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.02 | ||
| Debt/FCF | 0.12 | ||
| Altman-Z | 84.93 |
ROIC/WACC2.33
WACC7.34%
2.3 Liquidity
- A Current Ratio of 6.03 indicates that GE9 has no problem at all paying its short term obligations.
- Looking at the Current ratio, with a value of 6.03, GE9 belongs to the top of the industry, outperforming 87.18% of the companies in the same industry.
- GE9 has a Quick Ratio of 6.01. This indicates that GE9 is financially healthy and has no problem in meeting its short term obligations.
- The Quick ratio of GE9 (6.01) is better than 87.18% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 6.03 | ||
| Quick Ratio | 6.01 |
3. Growth
3.1 Past
- The Earnings Per Share has grown by an impressive 125.90% over the past year.
- GE9 shows a strong growth in Earnings Per Share. Measured over the last years, the EPS has been growing by 28.38% yearly.
- GE9 shows a strong growth in Revenue. In the last year, the Revenue has grown by 24.66%.
- GE9 shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 31.16% yearly.
EPS 1Y (TTM)125.9%
EPS 3Y34.24%
EPS 5Y28.38%
EPS Q2Q%121.44%
Revenue 1Y (TTM)24.66%
Revenue growth 3Y32.63%
Revenue growth 5Y31.16%
Sales Q2Q%25.21%
3.2 Future
- Based on estimates for the next years, GE9 will show a quite strong growth in Earnings Per Share. The EPS will grow by 11.70% on average per year.
- Based on estimates for the next years, GE9 will show a quite strong growth in Revenue. The Revenue will grow by 14.39% on average per year.
EPS Next Y6.42%
EPS Next 2Y-1.8%
EPS Next 3Y6.27%
EPS Next 5Y11.7%
Revenue Next Year22.77%
Revenue Next 2Y19.6%
Revenue Next 3Y17.39%
Revenue Next 5Y14.39%
3.3 Evolution
- The estimated forward EPS growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
- Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
4. Valuation
4.1 Price/Earnings Ratio
- With a Price/Earnings ratio of 12.50, GE9 is valued correctly.
- 94.87% of the companies in the same industry are more expensive than GE9, based on the Price/Earnings ratio.
- The average S&P500 Price/Earnings ratio is at 26.99. GE9 is valued rather cheaply when compared to this.
- A Price/Forward Earnings ratio of 17.36 indicates a rather expensive valuation of GE9.
- 92.31% of the companies in the same industry are more expensive than GE9, based on the Price/Forward Earnings ratio.
- GE9's Price/Forward Earnings ratio indicates a valuation a bit cheaper than the S&P500 average which is at 28.06.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 12.5 | ||
| Fwd PE | 17.36 |
4.2 Price Multiples
- 74.36% of the companies in the same industry are more expensive than GE9, based on the Enterprise Value to EBITDA ratio.
- 82.05% of the companies in the same industry are more expensive than GE9, based on the Price/Free Cash Flow ratio.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 150.08 | ||
| EV/EBITDA | 122.17 |
4.3 Compensation for Growth
- The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates an expensive valuation of the company.
- GE9 has an outstanding profitability rating, which may justify a higher PE ratio.
PEG (NY)1.95
PEG (5Y)0.44
EPS Next 2Y-1.8%
EPS Next 3Y6.27%
5. Dividend
5.1 Amount
- No dividends for GE9!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
FRA:GE9 (2/20/2026, 7:00:00 PM)
249.5
+8.7 (+3.61%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)02-05 2026-02-05/amc
Earnings (Next)05-07 2026-05-07
Inst Owners44.16%
Inst Owner ChangeN/A
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap153.69B
Revenue(TTM)3.58B
Net Income(TTM)1.48B
Analysts73.08
Price Target297.36 (19.18%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr YearsN/A
Div Non Decr YearsN/A
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)30.75%
Min EPS beat(2)25.14%
Max EPS beat(2)36.36%
EPS beat(4)4
Avg EPS beat(4)61.45%
Min EPS beat(4)25.14%
Max EPS beat(4)134.67%
EPS beat(8)6
Avg EPS beat(8)30.99%
EPS beat(12)8
Avg EPS beat(12)16.81%
EPS beat(16)12
Avg EPS beat(16)30.22%
Revenue beat(2)1
Avg Revenue beat(2)-0.2%
Min Revenue beat(2)-1.49%
Max Revenue beat(2)1.09%
Revenue beat(4)2
Avg Revenue beat(4)-1.55%
Min Revenue beat(4)-7.66%
Max Revenue beat(4)1.84%
Revenue beat(8)4
Avg Revenue beat(8)0.21%
Revenue beat(12)6
Avg Revenue beat(12)0.66%
Revenue beat(16)10
Avg Revenue beat(16)2.34%
PT rev (1m)3.38%
PT rev (3m)N/A
EPS NQ rev (1m)0.11%
EPS NQ rev (3m)N/A
EPS NY rev (1m)3.51%
EPS NY rev (3m)N/A
Revenue NQ rev (1m)0.95%
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)N/A
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 12.5 | ||
| Fwd PE | 17.36 | ||
| P/S | 50.42 | ||
| P/FCF | 150.08 | ||
| P/OCF | 141.71 | ||
| P/B | 31.41 | ||
| P/tB | 49.52 | ||
| EV/EBITDA | 122.17 |
EPS(TTM)19.96
EY8%
EPS(NY)14.37
Fwd EY5.76%
FCF(TTM)1.66
FCFY0.67%
OCF(TTM)1.76
OCFY0.71%
SpS4.95
BVpS7.94
TBVpS5.04
PEG (NY)1.95
PEG (5Y)0.44
Graham Number59.73
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 21.1% | ||
| ROE | 25.76% | ||
| ROCE | 21.02% | ||
| ROIC | 17.11% | ||
| ROICexc | 37.46% | ||
| ROICexgc | 140.29% | ||
| OM | 36.85% | ||
| PM (TTM) | 41.35% | ||
| GM | 94.27% | ||
| FCFM | 33.59% |
ROA(3y)15.92%
ROA(5y)16.24%
ROE(3y)18.48%
ROE(5y)18.5%
ROIC(3y)15.2%
ROIC(5y)16.1%
ROICexc(3y)68.77%
ROICexc(5y)79.83%
ROICexgc(3y)104.16%
ROICexgc(5y)104.49%
ROCE(3y)18.68%
ROCE(5y)19.78%
ROICexgc growth 3Y22.66%
ROICexgc growth 5Y11.4%
ROICexc growth 3Y-22.7%
ROICexc growth 5Y-14.09%
OM growth 3Y-2.13%
OM growth 5Y-7.73%
PM growth 3Y1.23%
PM growth 5Y-2.03%
GM growth 3Y-1.55%
GM growth 5YN/A
F-Score7
Asset Turnover0.51
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.02 | ||
| Debt/FCF | 0.12 | ||
| Debt/EBITDA | 0.09 | ||
| Cap/Depr | 106.94% | ||
| Cap/Sales | 1.98% | ||
| Interest Coverage | 243.04 | ||
| Cash Conversion | 91.92% | ||
| Profit Quality | 81.24% | ||
| Current Ratio | 6.03 | ||
| Quick Ratio | 6.01 | ||
| Altman-Z | 84.93 |
F-Score7
WACC7.34%
ROIC/WACC2.33
Cap/Depr(3y)96.21%
Cap/Depr(5y)101.76%
Cap/Sales(3y)1.96%
Cap/Sales(5y)2.38%
Profit Quality(3y)107.36%
Profit Quality(5y)103.53%
High Growth Momentum
Growth
EPS 1Y (TTM)125.9%
EPS 3Y34.24%
EPS 5Y28.38%
EPS Q2Q%121.44%
EPS Next Y6.42%
EPS Next 2Y-1.8%
EPS Next 3Y6.27%
EPS Next 5Y11.7%
Revenue 1Y (TTM)24.66%
Revenue growth 3Y32.63%
Revenue growth 5Y31.16%
Sales Q2Q%25.21%
Revenue Next Year22.77%
Revenue Next 2Y19.6%
Revenue Next 3Y17.39%
Revenue Next 5Y14.39%
EBIT growth 1Y41.76%
EBIT growth 3Y29.8%
EBIT growth 5Y21.02%
EBIT Next Year56.34%
EBIT Next 3Y28.03%
EBIT Next 5Y19.44%
FCF growth 1Y46.62%
FCF growth 3Y51.06%
FCF growth 5Y42.84%
OCF growth 1Y44.68%
OCF growth 3Y47.08%
OCF growth 5Y41.48%
GENMAB A/S / GE9.DE FAQ
Can you provide the ChartMill fundamental rating for GENMAB A/S?
ChartMill assigns a fundamental rating of 7 / 10 to GE9.DE.
Can you provide the valuation status for GENMAB A/S?
ChartMill assigns a valuation rating of 6 / 10 to GENMAB A/S (GE9.DE). This can be considered as Fairly Valued.
How profitable is GENMAB A/S (GE9.DE) stock?
GENMAB A/S (GE9.DE) has a profitability rating of 8 / 10.
What are the PE and PB ratios of GENMAB A/S (GE9.DE) stock?
The Price/Earnings (PE) ratio for GENMAB A/S (GE9.DE) is 12.5 and the Price/Book (PB) ratio is 31.41.
What is the expected EPS growth for GENMAB A/S (GE9.DE) stock?
The Earnings per Share (EPS) of GENMAB A/S (GE9.DE) is expected to grow by 6.42% in the next year.